|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Avanti Polar Lipids Inc., of Alabaster, Ala., was awarded a Phase II Small Business Innovation Research Grant from the National Diabetes and Digestive and Kidney Diseases to test a food supplement, Lym-X-Sorb in cystic fibrosis patients. Lym-X-Sorb is designed to allow absorption of essential fatty acids and choline. The trial will enroll 78 CF patients, 6 years and older, with pancreatic insufficiency to evaluate the drug's effects over 18 months on patients' essential fatty acid status, fat soluble vitamin status, respiratory and pulmonary functions, growth rate and overall health.
o Avid Radiopharmaceuticals Inc., of Philadelphia, and Schering AG, of Berlin, ...